Why Are Neovasc Shares Moving Higher On Thursday?

The FDA approved the Investigational Device Exemption for Neovasc Inc's NVCN COSIRA-II IDE Clinical Trial regarding the Neovasc Reducer.
Related Content: Real-World Study Shows Neovasc's Reducer Is Safe, Efficacious In Patients With Refractory Angina.
The Company remains on track to enroll the first patient in the U.S. trial by the end of 2021.
COSIRA-II is a randomized, sham-controlled trial investigating the safety and effectiveness of the Reducer for patients suffering from refractory angina.
The trial's primary endpoint is a change in exercise tolerance testing time between baseline and six-month follow-up.
The will enroll approximately 380 patients.
Related content: Benzinga's Full FDA Calendar.
Price Action: NVCN shares are up 2.85% at $0.76 during the market session on the last check Thursday.